KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–Feb. 12, 2026– KalVista Pharmaceuticals, Inc…. read more.
PTC Therapeutics Inc. announced that it has withdrawn the New Drug Application (NDA) resubmission for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following… read more.
American women now have the option of screening for cervical cancer at home, using newly approved self-collection tools. While experts hope this will increase uptake in the under-screened population, a… read more.
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS… read more.
Key data from Merck’s portfolio and pipeline to be presented at the 2026 ASCO GU Cancers Symposium: First-time data from the Phase 3 KEYNOTE-B15/EV-304 trial evaluating KEYTRUDA, Merck’s… read more.
Biofrontera Inc. announced that the FDA has completed its filing review and accepted filing of the Company’s supplemental New Drug Application (sNDA) for Ameluz (aminolevulinic acid hydrochloride) topical… read more.
Texas Children’s once again continues to lead the nation in performing the most pediatric transplants, as reported by the Organ Procurement & Transplantation Network (OPTN), the country’s unique public-private… read more.
After developing an AI tool that recommends antidepressants based on medical history, George Mason University researchers are now examining whether additional patient demographics, such as race and ethnicity, can improve the… read more.
Ono Pharmaceutical Co., Ltd. announced that the FDA has accepted for filing the New Drug Application (NDA) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible,… read more.
In the U.S., one in eight women will get breast cancer in their lifetime, and about half of them will have mastectomies. Many of those women opt to… read more.
Pharmaceutical products are essential for health, and they play and will continue to play a key role in disease prevention and treatment. However, they are exerting a major… read more.
Pfizer Inc. announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating Braftovi (encorafenib) in combination with cetuximab (Erbitux) and FOLFIRI (fluorouracil,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
